Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes

克里唑蒂尼 医学 肺癌 内科学 间变性淋巴瘤激酶 肿瘤科 融合基因 血液学 胃肠病学 碱性抑制剂 基因 生物 遗传学 恶性胸腔积液
作者
Panwen Tian,Yujie Liu,Hao Zeng,Yuan Tang,Analyn Lizaso,Junyi Ye,Lin Shao,Yalun Li
出处
期刊:Journal of Cancer Research and Clinical Oncology [Springer Science+Business Media]
卷期号:146 (4): 935-944 被引量:29
标识
DOI:10.1007/s00432-019-03116-6
摘要

This study aimed to determine the molecular features and clinical outcomes of young patients with non-small cell lung cancer (NSCLC) harboring ALK fusion genes. We interrogated the genomic profile of 1652 patients with lung cancer who underwent targeted next-generation sequencing to screen for candidate oncogenic drivers using histological specimens acquired from January 2016 to December 2018. ALK fusions were identified in 101 NSCLC patients, and 52 of them were diagnosed before the age of 50 years (52/367, 14.2%). Of the 52 patients with early-onset disease, 22 (42.3%) were male and 43 (82.7%) never smoked; the median patient age was 44 years (range 28–50 years). The most frequently occurring ALK fusion partner was EML4, which was identified in 80.8% (42/52) of young patients. Compared to the older patients, patients with early-onset disease were more likely to harbor EML4-ALK variant 1 (38.5% vs. 14.3%; P = 0.007). We also identified rare ALK fusions, including CHRNA7-ALK, TACR1-ALK, HIP1-ALK, DYSF-ALK and ITGAV-ALK, in patients with early-onset disease, and patients with these fusions responded well to crizotinib treatment. A statistically significant difference was observed in progression-free survival (PFS) between the young patients and older patients who received crizotinib as the first-line therapy (17.5 months vs 9.0 months, P = 0.048). However, the median PFS of young patients harboring concurrent TP53 mutations was only 6.2 months. Unique genetic characteristics were found in ALK-rearranged NSCLC patients with early disease onset, and these patients responded better to crizotinib and had longer PFS compared to patients with later disease onset. However, patients with concomitant TP53 mutations may not have a significant response to treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
123完成签到,获得积分20
2秒前
华仔应助hyc采纳,获得10
2秒前
2秒前
咕嘟发布了新的文献求助10
2秒前
兔年吉祥完成签到,获得积分10
3秒前
owlhealth完成签到,获得积分10
3秒前
Orange应助llll采纳,获得10
4秒前
4秒前
大椒发布了新的文献求助10
4秒前
俞晓发布了新的文献求助10
4秒前
4秒前
冷青完成签到,获得积分10
5秒前
PT177245完成签到,获得积分10
5秒前
年轻小之发布了新的文献求助10
6秒前
搜集达人应助布溜采纳,获得10
6秒前
witty发布了新的文献求助10
7秒前
小鹿呀发布了新的文献求助10
9秒前
10秒前
搜集达人应助WSGQT采纳,获得10
10秒前
11秒前
hei发布了新的文献求助20
13秒前
888发布了新的文献求助10
15秒前
584178682发布了新的文献求助10
15秒前
lina发布了新的文献求助10
16秒前
16秒前
俞晓完成签到 ,获得积分10
17秒前
菜头完成签到,获得积分10
18秒前
梦醒了完成签到 ,获得积分10
18秒前
19秒前
123发布了新的文献求助10
21秒前
量子星尘发布了新的文献求助10
22秒前
传奇3应助沐晴采纳,获得10
23秒前
24秒前
调皮的靖易完成签到,获得积分10
25秒前
大力发布了新的文献求助10
25秒前
领导范儿应助现代子默采纳,获得10
26秒前
小刘发布了新的文献求助10
27秒前
草字头完成签到,获得积分10
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988827
求助须知:如何正确求助?哪些是违规求助? 3531197
关于积分的说明 11252739
捐赠科研通 3269830
什么是DOI,文献DOI怎么找? 1804815
邀请新用户注册赠送积分活动 881915
科研通“疑难数据库(出版商)”最低求助积分说明 809028